Molecular Imaging

分子成像项目（MIP）由来自7个不同部门的19名成员组成。自上一个资助周期以来，该项目的研究基础从年度直接研究支持总额5,740,595美元增加了46%，其中6,393,909美元来自NCI。在最近的资助期内，分子成像项目发表了188篇论文，其中28.7%是项目内的，36.7%是项目间的。该项目在开发促进癌症诊断和治疗的新技术方面取得了重大进展，并提供了方法和试剂，可以在临床前和临床环境中实时监测各种治疗方法的疗效。这些进展包括新的分子成像报告分子的发展，这提高了我们对癌症病因学、生物学、病理生理学和治疗的理解。我们将继续开发先进的方法来成像存在的恶性前（发育不良）组织和致癌信号分子在体内。我们开发了一种集成的光学分子成像策略，使用荧光肽作为探针来靶向体内恶性前（发育不良）组织的存在。Thomas Wang MD， Stanford University博士的加入为MIP提供了新的能力，特别是新型光学成像探针和仪器的开发，可用于各种器官的早期癌症诊断筛查。Ross， Rehemtulla和Luker博士将继续开发和验证分子成像报告蛋白（即CXCR， c-Met和Akt），细胞和动物的非侵入性成像将用于评估这些新的报告蛋白结构，以检测关键的致癌信号通路。这些工具和概念将极大地帮助我们的临床前药物开发过程，并为更有效的肿瘤联合治疗策略提供见解。Ross， Meyer和Chenevert博士将继续开发基于核磁共振成像的新型替代品，以量化癌症患者的早期治疗效果。该领域最近的突破包括分析个体体素（参数反应映射，PRM）随时间变化的概念，提供了比当前方法更稳健和更具预测性的治疗反应定量测量。将PRM概念应用于脑、乳腺、头颈部以及转移到骨的前列腺癌的临床试验，已经产生的结果证明了核磁共振成像的早期预测能力，特别是当与PRM分析相结合时。

The Molecular Imaging Program (MIP) consists of 19 members from 7 different departments. Since the last funding cycle the research base of the Program increased 46% from $5,740,595 total annual direct research support, of which $6,393,909 Is from the NCI. Over this last grant period, there were 188 publications of the Molecular Imaging Program, of which 28,7% were intra-programmatic and 36,7% were inter-programmatic. The program has made significant advances in developing novel technologies that facilitate diagnosis and treatment of cancer, and also has provided methodologies and reagents wherein the efficacy of various therapeutics can be monitored in real-time in pre-clinical and clinical settings. These advances include the development of novel molecular Imaging reporter molecules which have Improved our understanding of cancer etiology, biology, pathophysiology and therapy. We will continue to develop cutting edge approaches for imaging the presence of pre-malignant (dysplastic) tissue and oncogenic signaling molecules in vivo. We have developed an Integrated optical molecular Imaging strategy that uses fluorescence peptides as probes to target the presence of pre-malignant (dysplastic) tissue in vivo. The recruitment of Thomas Wang MD, PhD from Stanford University provides the MIP with new capabilities, especially the development of novel optical Imaging probes and instrumentation that can be used as a diagnostic cancer screen for early detection in variousorgans. Drs Ross, Rehemtulla and Luker will continue to develop and validate molecular imaging reporters (i.e. CXCR, c-Met and Akt), Non-invasive imaging in cells and animals will be used to evaluate these novel reporter constructs for detection of key oncogenic signaling pathways. These tools and concepts should significantly aid in our preclinical drug development process and provide insights into more efficacious combination therapy strategies for tumors. Drs Ross, Meyer and Chenevert will continue to develop novel MR-imaging based surrogates for quantification of early therapeutic efficacy in cancer patients. Recent breakthroughs in this area include the concept that analysis of changes within individual voxels (parametric response mapping, PRM) over time, provide a much more robust and predictive quantitative measure of treatment response than current approaches. Application of the PRM concept to clinical trials in brain, breast, head and neck as well as in prostate cancer metastatic to bone, have yielded results that demonstrate the early predictive power of MR-imaging especially when combined with PRM analysis.